Michael C A
Br J Clin Pharmacol. 1982 Jun;13(1 Suppl):127S-131S. doi: 10.1111/j.1365-2125.1982.tb01901.x.
1 Eighty-five women with severe hypertension complicating pregnancy were treated with oral labetalol (Trandate). Six of these had a twin pregnancy and 54 had proteinuria. 2 Effective control of the blood pressure was achieved in all but six patients. The maximum dose of labetalol prescribed was 1200 mg daily. There were no significant maternal or foetal side-effects. 3 Foeto-placental function was carefully monitored in all patients. Twenty-four of the 89 infants born alive showed evidence of intra-uterine growth retardation, the highest incidence occurring in the group of patients with essential hypertension complicated by pregnancy induced hypertension. 4 The low perinatal mortality of 4.4% was a reflection of the meticulous control of the blood pressure. 5 There were no congenital malformations or evidence of oculotoxicity in any of the infants delivered. 6 The efficient hypotensive action of orally administered labetalol together with the absence of maternal and foetal side effects and consequent improved perinatal mortality confirms that it is an eminently suitable drug for the treatment of hypertension complicating pregnancy.
85名患有严重高血压并合并妊娠的女性接受了口服拉贝洛尔（降压乐）治疗。其中6名怀有双胎，54名有蛋白尿。
除6名患者外，所有患者的血压均得到有效控制。拉贝洛尔的最大处方剂量为每日1200毫克。未出现明显的母体或胎儿副作用。
对所有患者的胎儿 - 胎盘功能进行了仔细监测。89名存活婴儿中有24名有宫内生长迟缓的迹象，最高发病率出现在原发性高血压合并妊娠高血压综合征的患者组中。
4.4%的低围产期死亡率反映了对血压的精心控制。
所有分娩的婴儿均无先天性畸形或眼毒性迹象。
口服拉贝洛尔有效的降压作用，以及无母体和胎儿副作用并因此改善围产期死亡率，证实它是治疗妊娠合并高血压的极为合适的药物。
